$5.65 -0.10 (-1.74%)
11/6/2009 4:00 PM

Accuray, Inc. (ARAY)

CAPS Rating: 4 out of 5

The Company has developed the commercially available intelligent robotic radiosurgery system, the CyberKnife system, designed to treat solid tumors anywhere in the body as an alternative to traditional surgery.

Current Price $5.65 Mkt Cap $320.34M
Open $5.67 P/E Ratio 575.00
Prev. Close $5.75 Div. (Yield) N/A (N/A)
Daily Range $5.58 - $5.74 Volume 132,238
52-Wk Range $3.70 - $8.35 Avg. Daily Vol. 254,000

ARAY News and Commentary

Caps

How do you think ARAY will perform vs the S&P 500?

Add Stock to Watchlist

All Members

519 Outperform
26 Underperform
 

All-Star Members

164 Outperform
8 Underperform
 

Wall Street

1 Outperform
3 Underperform
 

Top ARAY Bull/Bear Pitches

The best Bull and Bear pitches based on recency and number of recommendations.

rknapton (86.78)
Submitted July 12, 2009

Accuray Inc. (ARAY)

Here’s a stock I stumbled upon this past weekend while my Mom was visiting. A commercial appeared on TV advertising the “CyberKnife”, and my Mom mentioned how someone she knew had traveled to Colorado Springs to undergo… More

1 Comment | Reply | Report this Post

taklamakan (48.02)
Submitted March 21, 2008

Down in an up market, down vs. sector, down vs. competitors, down, down, down. Outstanding maybe as a short, promising technology and product, but hopeless as an investment, whatever the reason (management, board, credit crisis, etc...) Going down in… More

1 Comment | Reply | Report this Post
ARAY VS S&P 500 (SPY)

Recent Community Commentary

Read the most recent pitches from members about ARAY.

Recs

0
Member Avatar harryplotter (< 20) Submitted: 9/18/2009 11:51:52 PM : Underperform Start Price: $6.55 ARAY Score: +14.91

I work with CyberKnife. It is a good technology, but I don't think it is a good investment. Several problems: (1) CyberKnife is actually not a surgical tool, it is a radiation oncology tool (the surgeons and radiation oncologists are actually battling the turf now); (2) The radiation oncology has a dominant toy maker called Varian that won't let this company eat their lunch; (3) Radiation oncology market is very saturated, not much room for them to grow (some niche area, but not much else); (4) Reimbursement for CyberKnife has been cut left and right, practitioners have been leaving this for other better-paying procedures; (5) Technology-wise, they don't have any significant improvement in the pipeline.

Report this Post 2 Comments | Reply | Permalink

Recs

0
Member Avatar ssbb123 (78.24) Submitted: 9/8/2009 10:37:54 PM : Outperform Start Price: $6.47 ARAY Score: -17.06

Maker of the Cyberknife non-invasive cancer killer.
No more chemo and invasive surgery?? sounds good to me.
$600 million backlog of orders, 25% contingent due to the poor economy. When the economy picks up it will take off.

Report this Post 3 Comments | Reply | Permalink

Recs

0
Member Avatar chopchop0 (41.31) Submitted: 8/26/2009 7:29:09 PM : Underperform Start Price: $6.45 ARAY Score: +16.82

ARAY is overhyped. The cyberknife is a fancy tool, but not very versatile and actually quite limited in many respects.

It provides NO image guidance of the tumor besides orthogonal imaging, which the robot arm must track off of. There is no ability to obtain 3-dimensional imaging like a cone beam CT.

Moreover, as capital budgets get slashed, institutions and practices are going to buy the ONE machine that can do everything a cyberknife does and more, the Varian Trilogy with RapidArc. It can do regular RT treatments or radiosurgery anywhere in the body.

Report this Post 1 Comment | Reply | Permalink
View All 112 Pitches »

Leaderboard

Find the members with the highest scoring picks in ARAY.

Score Leader

volumewhiz

volumewhiz (99.63) Score: +64.15

The Score Leader is the member with the highest score across all their picks in ARAY.

Top
Pick 		Member Name Member
Rating 		Start
Date 		Call Time
Frame 		Start
Price 		Stock
Gain 		S&P
Gain 		Score Commentary
dzirak 89.49 10/25/2007 Underperform 1Y $17.60 -67.89% -25.66% +42.23
vega4 90.10 7/1/2009 Underperform 5Y $6.75 -16.30% +16.52% +32.82
vrag 65.32 2/5/2008 Underperform NS $10.51 -46.24% -17.23% +29.01
bonz123 61.19 3/3/2008 Underperform NS $10.26 -44.93% -16.14% +28.79
SYDAX 98.63 5/21/2009 Underperform 1Y $6.00 -5.83% +21.00% +26.83
Nivaos 37.93 8/17/2009 Underperform 1Y $6.82 -17.16% +8.90% +26.05
SanDieguito < 20 1/31/2008 Underperform 1Y $9.88 -42.81% -17.00% +25.81
harryhotspur1403 < 20 10/22/2008 4/22/2009 Underperform 1Y $6.11 -7.53% +17.86% +25.39
trade888 < 20 7/22/2009 Underperform 5Y $6.47 -12.67% +12.59% +25.26
bhayek 98.39 10/2/2008 Underperform 1Y $7.63 -25.95% -1.75% +24.20
View Complete Scorecard »

Wall Street

See what the Wall Street professionals think, according to their public statements and filings.

Member Name Member
Rating		 Start
Date		 Call Time
Frame		 Start
Price		 Stock
Gain		 S&P
Gain		 Score End Date Commentary
TrackSoleil 83.54 7/29/2008 Outperform NS $8.34 -52.40% -43.80% -8.60 3/9/2009 @ $3.97
TrackUBS 86.41 6/13/2008 Underperform NS $8.62 -34.45% -17.40% +17.05
TrackOppenheimer 26.63 1/31/2008 Underperform NS $10.15 -44.33% -16.31% +28.03
TrackJimCramer < 20 10/24/2007 Underperform 3W $17.53 -67.77% -25.90% +41.87
TrackSoleil 83.54 6/1/2007 Outperform NS $23.42 -56.66% -11.39% -45.27 1/31/2008 @ $10.15
TrackJimCramer < 20 3/28/2007 Outperform 3W $22.85 -23.28% +6.81% -30.09 10/24/2007 @ $17.53
TrackPiperJaff 80.38 3/20/2007 Outperform NS $24.00 -76.46% -19.15% -57.31
TrackJefferies 75.83 3/20/2007 Outperform NS $24.00 -64.75% -8.27% -56.48 8/13/2008 @ $8.46

Featured Broker Partners